The 2025 Medtech Market Outlook - Vascular Robots

As investor interest and technological capabilities converge, large funding rounds are fueling commercialization efforts. Still, questions remain about proving clinical and economic value to both providers and patients, and the onus is on robotic platforms to demonstrate meaningful benefits beyond conventional approaches.

Nick Talamantes  0:00  
So a fun one for us that we've been following. You know, we do hear a lot of talk in the industry about surgical robotics, and we think that this is the year where, and really it started, I believe, kind of towards the end of last year, but this is the year where we see Endovascular vascular robotics take off. There's so much opportunity what they can do here, specifically, when you're looking at certain types of diseases being pursued, stroke comes to mind for me that we're now seeing that the technology has reached a point, the interest in the technology, the adoption and appetite for this technology, has kind of reached a climax here, and we're starting to see some large rounds going out to support the adoption and commercialization of these technologies. That being said, I would consider myself something of a surgical, robotic skeptic. We can talk about it anytime, but I think that there is a lot of work that needs to be done to show that this is something that's really adding value to the provider and to the patient. I think that the with the with certain indications, there's absolutely no doubt an argument to be made that there's been for a surgical robot and the value that they can bring and that's that burden is going to fall towards the surgical robotics companies, especially as they get into this new market. So.


 

LSI Asia ‘25 is filling fast. Secure your spot today to join Medtech and Healthtech leaders.

June 10th - 13th, 2025The Ritz-Carlton, Millenia Singapore Register arrow